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Chlorpromazine (CPZ), an antipsychotic agent shown to inhibit the action of various neurophysiological receptors, also exhibits
preferential association with the plasma membrane, inducing stomatocytic morphological response in red blood cells (RBC). Given the
cationic nature of CPZ, fluorimetry, pH titration, and red cell morphological studies were performed to assess the associative predilection of
CPZ for anionic membrane components. CPZ fluorescence intensity increased 320–370% upon addition of phosphatidylcholine (PC) small
unilamellar vesicles (SUVs) to aqueous CPZ, indicating an affinity of the drug for lipidic phases. After removal of unbound drug, CPZ
fluorescence increased up to 92% with increasing phosphatidylserine (PS) in the lipid phase (up to 30 mol% of total lipid), suggesting a
preferential association of the drug with anionic lipids. In studies of pH titration, the pKa of CPZ in the presence of Triton X-100 micelles or
phospholipid SUVs increased with increasing anionicity of the lipidic phase [7.8 with Triton X-100, 8.0 with PC, 8.3 with
phosphatidylglycerol (PG)], lending further support to preferential drug interaction with anionic lipidic components. At 0 jC, CPZ-
induced red cell shape change was less extensive in cells made echinocytic by adenosine triphosphate (ATP) depletion, compared to cells
made echinocytic by PS treatment following vanadate preincubation. This suggests that polyphosphoinositide lipids are CPZ membrane
binding sites. Since polyphosphoinositide lipids are implicated as important intermediates in a number of receptor-mediated cell signaling
pathways, evidence of association with these specific lipids provides a means by which psychoactive drugs may induce neurophysiological
effects through direct interaction with general membrane components.
D 2003 Elsevier B.V. All rights reserved.Keywords: Chlorpromazine; Electrostatic; Amphipathic; Membrane; Erythrocyte; Fluorescence0005-2736/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
doi:10.1016/S0005-2736(03)00229-3
Abbreviations: ATP, adenosine triphosphate; CPZ, chlorpromazine; DAG, diacylglycerol; DLPC, dilauroylphosphatidylcholine; DLPS, dilauroylphos-
phatidylserine; DMPC, dimyristoylphosphatidylcholine; DMPG, dimyristoylphosphatidylglycerol; DMPS, dimyristoylphosphatidylserine; HCT, hematocrit;
NADH, h-nicotinamide adenine dinucleotide; PA, phosphatidic acid; PBS, phosphate-buffered saline; PC, phosphatidylcholine; PG, phosphatidylglycerol; PI,
phosphatidylinositol; PIP2, phosphatidylinositol-4,5-bisphosphate; PS, phosphatidylserine; RBC, red blood cells; SUVs, small unilamellar vesicles; Tris,
tris(hydroxymethyl)aminomethane
$ Supported by National Institutes of Health Grant HL23787; an IBM Faculty Research Grant from Santa Clara University; an Undergraduate Research
Grant from the Howard Hughes Medical Institute, awarded to F.C.C.; and National Science Foundation Grant CHE-9820382 (R.E.U.). A summer stipend for
C.M.H. through the NSF-REU program is gratefully acknowledged.
* Corresponding author. Tel.: +1-650-723-2503; fax: +1-650-723-4817.
E-mail address: whh@stanford.edu (W.H. Huestis).
1 Present address: SEED Intellectual Property Law Group PLLC, 701 Fifth Avenue, Suite 6300, Seattle, WA 98104.
2 Present address: Pharmaceutical Development Consultants LLC, 1115 Rainbow Boulevard, #120, Salida, CO 81201.
J.Y. Chen et al. / Biochimica et Biophysica Acta 1616 (2003) 95–105961. Introduction 2. Experimental proceduresThe phenothiazine family of drugs has been shown to
elicit a variety of neuroleptic effects. Chlorpromazine
(CPZ), one of the better-known phenothiazines, is an
antipsychotic agent used historically in the treatment of
schizophrenia. CPZ is believed to exert its antipsychotic
effects by blocking dopamine receptors; however, CPZ
also exerts effects upon muscarinic and a1-adrenergic
receptors, a possible reason for the many side effects
associated with this treatment (reviewed in Refs. [1,2];
see also Refs. [3–6]). Recently, CPZ has been shown to
hold promise as a treatment for prion-based afflictions
[7].
Other than by the blockage of specific cellular recep-
tors, the diverse effects of CPZ may also be attributable
to the amphipathic nature of the drug. The tricyclic ring
structure of CPZ is hydrophobic, partitioning with rela-
tive ease into the bulk hydrocarbon phase of membrane
bilayer systems, while the tertiary propylamine tail
region of the drug is hydrophilic, interacting well with
the polar headgroup regions of membrane bilayers [8].
Moreover, at physiological pH, the propylamine chain of
the drug is cationic. Because the inner leaflet of the
human red blood cell (RBC) plasma membrane bilayer
contains virtually all of the net anionic phospholipids
[9,10], electrostatic attractive forces may sequester CPZ
in the inner membrane leaflet [11]. In theory, such
accessibility of CPZ to the cytofacial surface of the cell
membrane would allow the drug to exert pharmacolog-
ical effects via direct interaction with intracellular pro-
cesses such as signal transduction or intracellular
trafficking. In normal discoid RBC, preferential accumu-
lation of CPZ expands the inner leaflet, causing the
membrane to buckle inward to produce a stomatocytic
morphology [11].
While many reports have discussed the importance of
hydrophobic and electrostatic forces in the interaction of
CPZ with membrane bilayers, detailed characterization of
these forces and their role in drug–membrane associa-
tions is lacking. The relative extent to which CPZ–
membrane interactions are dictated by hydrophobic ver-
sus electrostatic effects remains largely unclear. Further,
it is unclear whether the electrostatic interactions of CPZ
with the membrane are dictated more by the presence of
the abundant anionic lipid phosphatidylserine (PS) (net
charge  1 at physiological pH) or the polyphosphoino-
sitide lipids (present in very small quantities in the
membrane, but each carrying a localized net charge of
 3 or  5 at physiological pH).
In this investigation, fluorescence and titration studies
are presented elucidating the electrostatic nature of CPZ
binding to membranes. In addition, preferential binding
of CPZ to specific anionic phospholipid classes is
examined through studies altering RBC membrane phos-
pholipid content and transbilayer distribution.2.1. Materials
Chlorpromazine hydrochloride (CPZ), sodium orthova-
nadate (vanadate), 25% glutaraldehyde solution (grade I),
Triton X-100, dilauroylphosphatidylcholine (DLPC),
dimyristoylphosphatidylcholine (DMPC), inosine, and
adenosine were obtained from Sigma Chemical Co. (St.
Louis, MO). Adenosine triphosphate (ATP) assay kit was
obtained from Sigma Diagnostics (St. Louis, MO). Dimyr-
istoylphosphatidylserine (DMPS) was obtained from
Avanti Polar Lipids, Inc. (Alabaster, AL). Dilauroylphos-
phatidylserine (DLPS) was obtained from Calbiochem (San
Diego, CA). Dimyristoylphosphatidylglycerol (DMPG)
was obtained both from Sigma and Avanti. Penicillin–
Streptomycin (lyophilized powder) was obtained both from
Sigma and Gibco BRL (Gaithersburg, MD). All other
chemicals were reagent grade.
2.2. Vesicle preparation
Stock lipid solutions (typically in chloroformFmethanol)
were dried down under a gentle stream of argon or nitrogen,
then resuspended in phosphate-buffered saline (PBS; 138
mM NaCl, 5 mM KCl, 7.5 mM sodium phosphate, 1 mM
MgSO4, 5 mM glucose, pH 7.4) or NaCl/tris(hydroxyme-
thyl)aminomethane (Tris) buffer (140 mM NaCl, 10 mM
Tris, pH 7.4). Suspensions were bath-sonicated to clarity, to
produce small unilamellar vesicles (SUVs). In experiments
employing PS, magnesium (and occasionally glucose) was
omitted from PBS and sonication was carried out under
argon. SUVs in CPZ titrations were prepared by probe
sonication (Heat Systems, Inc., Farmingdale, NY), fol-
lowed by brief centrifugation to pellet and remove metal
debris.
2.3. Separation of free CPZ from CPZ bound to model
membranes
Samples of SUVs (0.2–1 mM phospholipid, composed
of DLPC plus 0–30 mol% DMPS) were incubated with
up to 120 AM CPZ for at least 20 min at ambient
temperature, incubation conditions allowing CPZ to in-
duce stable stomatocytosis in RBC [12]. Samples then
were subjected to ultrafiltration via centrifugation at
6000 g, using Nanosep Omega ultrafiltration units hav-
ing a molecular weight cutoff of 30 kDa (Pall Corpora-
tion, Ann Arbor, MI). This process allows low molecular
weight components (such as free unbound drug mole-
cules) to filter through (the filtrate), while retaining high
molecular weight components (such as drug molecules
associated with SUVs) atop the filter (the retentate). After
washing ultrafiltration units twice with buffer by centri-
fugation, sample filtrates and retentates were resuspended
in buffer (to 1 ml total volume each) and kept at 25 jC
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ple application, ultrafiltration units were seasoned via
centrifugation with CPZ (0.6–1.2 mM in 150 mM
NaCl(aq)), followed by extensive washing with 150 mM
NaCl(aq) and NaCl/Tris buffer.
2.4. Fluorescence studies of CPZ in model membrane
systems (after Ref. [13])
Filtrate and retentate solutions proceeding from ultrafil-
tration of CPZ-treated SUV samples were exposed to near-
UV radiation and analyzed for emission signal intensity of
CPZ fluorescence at the excitation and emission wave-
lengths indicated, for 3.5 min at 15-s intervals (Fluorolog-
3 spectrofluorimeter, Model FL3-22, Instruments S.A.,
Inc., Edison, NJ). Drug fluorescence emission for each
sample was expressed as the average of the final 105 s of
readings. Alternatively, samples not subjected to ultrafil-
tration were analyzed for CPZ fluorescence emission
signal intensity at the excitation and emission wavelengths
indicated, by acquisition of single instantaneous signal
readings.
2.5. Titration of CPZ in model membrane systems
CPZ (3.25 mM) and model membranes [micelles of
3.1% Triton X-100 (v/v)], or SUVs (22.5 mM DLPC with
either 2.5 mM DMPC, DMPS, or DMPG) were combined,
and suspended to an initial volume of 5 ml in 150 mM
NaCl. Solutions then were acidified slightly past the
neighboring equivalence point with HCl, before titrating
with 0.25–0.5 M NaOH in 3-Al aliquots. Titrations were
performed at ambient temperature with vortexing after
each addition of base, using a pH meter, model PHM82
(Radiometer, Copenhagen), with a combination semi-mi-
croelectrode (Corning, Corning, NY). Equivalence points
were identified at local maxima of first derivative plots
(generated by slope determination for each point, using
coordinates of the neighboring points). The pH at the
midpoint between equivalence points was defined as the
pKa of the drug.
2.6. Preparation of RBC
Human blood was obtained from healthy volunteers by
venipuncture, and collected in tubes containing citrate
anticoagulant. RBC were washed four times by centrifu-
gation, in 150 mM NaCl, and the plasma and buffy coat
were discarded. Isolated RBC were resuspended in PBS,
and stored at 4 jC until ready for use. Cells were used
within 24 h of collection, and all cell samples were stored
and incubated in capped plastic tubes. Cells not used
within 12 h of collection were incubated briefly at 37 jC
in PBS before use, to restore metabolic activity. Such
treatment allowed cells used 23 h after venipuncture (with
intracellular ATP levels at 45% that found in freshly drawncells) to restore intracellular ATP levels to 75% of the ATP
level in fresh cells (assay conditions described below).
Final RBC concentrations were 20% hematocrit (HCT)
unless otherwise noted. For incubations lasting 6 h or
more, cell suspensions contained antibiotics (80–160 U
penicillin/ml, 80–160 Ag streptomycin/ml) to inhibit mi-
crobial growth.
2.7. Generation of graded echinocytic morphologies by
slow metabolic depletion
Cell samples were incubated in depletion buffer (glu-
cose-free PBS) for up to 33 h at 37 jC, to deplete
intracellular ATP stores. Control samples were incubated
concurrently in supplemented buffer (PBS containing 10
mM inosine, 10 mM glucose, and 1 mM adenosine), to keep
ATP levels replete. ATP-depleted samples exhibited echi-
nocytic morphology, while control samples retained disco-
cytic morphology, consistent with previous findings [14].
Cells with intermediate degrees of ATP depletion and
echinocytosis were generated by (a) removing aliquots of
the control sample, (b) washing and resuspending the cells
in depletion buffer, and (c) continuing incubation for the
times indicated in figure legends. Three to five times during
the course of the incubation, all samples were pelleted and
resuspended in fresh appropriate buffer. Following incuba-
tion, all samples were washed by centrifugation, and treated
further as indicated.
2.8. Incorporation of exogenous lipid into RBC
Following metabolic depletion, control and depleted
samples were treated with 100 AM vanadate for 20–50
min at ambient temperature, to inhibit aminophospholipid
translocator activity [15,16]. Control samples then were
treated with either DLPC or DLPS SUVs in glucose-free,
magnesium-free PBS for 40 min at ambient temperature.
Cells were washed by centrifugation and resuspended in
glucose-free PBS plus 100 AM vanadate, before further
treatment.
2.9. Measurement of intracellular ATP (after Ref. [17])
ATP-dependent conversion of the glycolytic intermedi-
ate 3-phosphoglycerate was monitored by the coupled
oxidation of h-nicotinamide adenine dinucleotide (NADH)
to NAD. Cell samples at 20% HCT were diluted 1:1 (v/v)
with trichloroacetic acid (TCA, 12% w/v). Following brief
centrifugation, supernatants were diluted to 17% (v/v)
with a solution containing NADH (0.12 mg/ml) and 3-
phosphoglyceric acid (7 mM buffered solution). After
addition of glyceraldehyde-3-phosphate dehydrogenase
(from rabbit muscle) and 3-phosphoglyceric phosphoki-
nase (from yeast) (final concentrations: 22 and 12 U/ml,
respectively), oxidation of NADH was monitored at 340
nm for 12 min at ambient temperature. Concentration
Fig. 1. Effect of phospholipid concentration on fluorescence emission
intensity of CPZ. Solutions of CPZ (120 AM in NaCl/Tris buffer) were
treated with small unilamellar vesicles composed of sonicated PC (70 mol%
DLPC, 30 mol% DMPC) at the total lipid concentrations indicated.
Samples then were analyzed for CPZ fluorescence emission signal intensity
(wavelength settings: excitation, 325 nm; emission, 453 nm) at ambient
temperature without further treatment. Indicated intensity values represent
acquisition of single emission readings per sample.
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0.02 mM.
2.10. CPZ-induced shape reversal of echinocytes generated
by metabolic depletion or exogenous lipid
Following lipid addition in control cells, ATP-depleted
and lipid-incorporated RBC samples were allowed to sit at 0
jC for 45 min, before treatment with 150 AM CPZ at 0 jC
for 40–65 min. Sample aliquots (less than 1% HCT) were
fixed (0.3% glutaraldehyde in glucose-free PBS) before and
after CPZ addition, and examined by light microscopy.
Individual cells were assigned a score based on shape
[18]. Discocytes were assigned a score of 0, while cells
exhibiting increasingly perturbed morphology were as-
signed scores of increasing absolute value: echinocytes were
assigned scores from + 1 (slightly echinocytic cells) to + 5
(spheroechinocytes), and stomatocytes were assigned scores
from  1 (monoinvaginated cells) to  4 (spherostomato-
cytes). The average score of a field of 100 cells was defined
as the morphological index (MI) of that sample [19].
Generally, multiple MI determinations of the same sample
generated standard deviations between determinations of no
more than 0.25 MI units, more typically no more than 0.15
MI units. At these CPZ concentrations, significant drug–
membrane interactions are reported, with limited cell lysis
[11,12,20–23].3. Results
Unless otherwise indicated, the following results are
representative findings from individual experiments.
3.1. CPZ fluorescence in model membrane systems
In a study of samples not subjected to ultrafiltration,
where only single fluorescence readings were taken per
sample, fluorescence of 120 AM CPZ increased with added
DLPC to 320% and 370% in the presence of 0.2 and 1.0
mM lipid, respectively (Table 1). A second experiment
examined the CPZ fluorescence response to lipid concen-Table 1













0 355 457 0.54 106
0.2 320 456 1.72 106
1.0 322 451 2.02 106
CPZ (120 AM) was admixed with sonicated DLPC at the concentrations
indicated, then analyzed for CPZ fluorescence emission signal intensity
(counts per second, cps) at the indicated wavelengths, selected for maximal
emission intensity.trations in the range 0.1–0.5 mM (Fig. 1). Again, dose-
dependent fluorescence increases were found as lipid was
increased to 0.2 mM, but above that lipid concentration,
fluorescence intensity varied little. These results are consis-
tent with formation of a saturable drug–lipid complex. The
studies detailed below were carried out using a uniform lipid
concentration of 1.0 mM, well into the saturated range of the
interaction. This concentration approximates the phospho-
lipid present in a 20% HCT suspension of RBC ([14];
reviewed in Ref. [24]), the HCT employed in whole-cell
experiments.
To assess the effect of membrane phospholipid compo-
sition on CPZ membrane binding, CPZ (120 AM) was
allowed to interact with SUVs containing 0–30 mol% PS,
then analyzed for CPZ fluorescence. SUVs without PS were
representative of the general lipid environment of the RBC
membrane outer leaflet, while SUVs containing 30% PS
approximated the lipid environment of the RBC membrane
inner leaflet [14]. As PS content was increased from 0% to
30%, the fluorescence of 120 AM CPZ samples increased
92% (Fig. 2, right hand data set). A similar fluorescence
enhancement was also observed at lower CPZ concentra-
tions (Fig. 2, center data set).
When incubated with SUV suspensions 0.95 mM in total
lipid (Fig. 2), CPZ samples exhibited an increase in emis-
sion intensity of 220–250% as drug concentration increased
5-fold (24–120 AM). These dose-dependent increases in
CPZ emission intensity with increasing amounts of PS
demonstrated the importance of anionic phospholipid (and
Fig. 2. Effect of PS on fluorescence emission intensity of CPZ at low and
high drug concentrations. Solutions of 0 AM CPZ (n= 1), 24 AM CPZ
(n= 2) or 120 AM CPZ (n= 4) in NaCl/Tris buffer were incubated with
small unilamellar vesicles (0.95 mM sonicated lipid composed of 70 mol%
DLPC, DMPS at the mole percentages indicated, with the remaining lipid
DMPC) for 45 min at ambient temperature. Each sample was then diluted
with one volume NaCl/Tris buffer and subjected to ultrafiltration as
described. Retentates were resuspended in NaCl/Tris buffer, diluted 4.4-fold
from original sample volumes, and analyzed for fluorescence emission of
the fraction of sample CPZ molecules bound to sample SUVs, as described
(wavelength settings: excitation, 319 nm; emission, 452 nm). Error bars
represent standard deviations.
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membrane bilayers.
3.2. pH titration of CPZ in model membrane systems
pKa values of CPZ were determined in model membrane
systems for lipid or detergent: CPZ ratios of 8:1–16:1,
approximating the ratios of cell lipid/drug used in the cell
studies of this and previous investigations [12]. At these
ratios and the concentrations indicated, solutions were clear
at titration start, with no discernible precipitation and little
or no increase in turbidity at higher pH, thereby overcoming
such drug effects observed in free aqueous solution [25].
To establish the pKa of CPZ in a nonionic environment,
the drug was titrated in the presence of Triton X-100
micelles. At a concentration of 3.1% (v/v) detergent (deter-
gent/drug molar ratio: 16:1), 3.25 mM CPZ titrated with
0.25 M NaOH produced a curve with equivalence points at
pH 5.9 and 9.4, resulting in a calculated pKa value of 7.8 for
this system (Fig. 3A). With Triton X-100 devoid of titratable
functionalities in this pH domain, and the nitrogen atom of
the CPZ heterocycle expected to titrate at a much lower pH
due to resonance stabilization effects, the observed pKa
represented titration exclusively at the propylamine function
of CPZ. Because detergent suspensions were in micellar
form (reviewed in Ref. [26]) while the following lipid
suspensions were in bilayer form, a sample of drug wastitrated at a reduced Triton X-100 concentration (detergent/
drug molar ratio: 4:1) to correspond to the concentration of
bulk lipid molecules exposed to the surrounding aqueous
medium in the bilayer samples. The observed pKa of CPZ
was not affected by such reduction in Triton X-100 con-
centration (data not shown).
To establish the pKa of CPZ in a zwitterionic phospho-
lipid environment, the drug was titrated in the presence of
phospholipid bilayers composed exclusively of phosphati-
dylcholine (PC). Titration of the propylamine of CPZ (3.25
mM) in the presence of SUVs composed of DLPC and
DMPC (22.5 and 2.5 mM, respectively; total lipid/drug
molar ratio: 8:1) generated a curve similar in appearance
to that with Triton X-100 (Fig. 3B). However, with PC
SUVs, the pKa of the propylamine of CPZ was 8.0, a
discernible increase over that with nonionic detergent. The
quantity of base needed to traverse from the first equiva-
lence point to the second was comparable when either Triton
X-100 or PC was used as the bulk amphiphile, indicating
that comparable numbers of CPZ molecules were deproto-
nated whether the bulk amphiphilic phase was in micellar or
bilayer form.
To assess the effect of anionic phospholipid on CPZ
titration, DMPS (net charge:  1 at pH 7.4) was substituted
for DMPC in SUVs and included with CPZ during titration.
This system generated only one detectable equivalence
point and first derivative maximum (Fig. 3C), producing a
simple sigmoidal titration curve. Thus, an accurate determi-
nation of CPZ pKa in the presence of PS was not possible by
this methodology. Possibly, concurrent titration of PS may
have complicated the titration of the drug [27].
To examine a different anionic lipid, CPZ was titrated in
the presence of phosphatidylglycerol (PG). A net anionic
lipid having no titratable groups in the pH region of interest
([27], review), PG should not have an independent effect on
the titration curve. Titration of 3.25 mM CPZ with SUV
suspensions of 22.5 mM DLPC and 2.5 mM DMPG, two
well-defined equivalence points were obtained, and the pKa
of CPZ in this system was determined to be 8.3 (Fig. 3D),
higher than those in the presence of either Triton X-100 or
PC alone. Thus, when excluded from the pKa range of the
drug, the presence of detergent or lipid in suspension with
CPZ promoted an increase of CPZ pKa with increasing lipid
anionicity. These results indicate that association with
anionic amphipaths raises the pKa of CPZ, such that at
physiological pH, a larger fraction of the drug is protonated.
3.3. Intracellular ATP of echinocytes generated by
metabolic depletion or exogenous lipid
Before incubation, initial ATP levels in untreated red
cells (at 20% HCT) were determined to be 0.25 mM,
consistent with reported values of ATP concentration in
normal human red cells [28]. Incubation of cell samples at
37 jC with supplemented PBS for 33 h allowed intracellular
ATP levels to double over initial levels (Fig. 4, bars A and B).
Fig. 4. ATP levels in metabolically depleted and lipid-induced echinocytes
(20%HCT). Cell samples were diluted to 20%HCT in the presence (B, C, D)
or absence (A, E) of sugar supplementation, then were incubated for 33 h
(B, C, D, E) with resuspension of cells twice in fresh buffer during the
course of the incubation. Samples in buffer containing 100 AM vanadate
then were treated with SUVs for 35 min at ambient temperature. Following
removal of unincorporated lipid, samples were diluted 1:1 (v/v) with TCA
(12% w/v), then quick-frozen and stored at  20 jC for ATP analysis as
described. A: sample before incubation; B, E: no lipid; C: 42 AM DLPS;
D: 24 AM DLPC; F: 0.1 mM ATP standard.
Fig. 3. Titration curve of CPZ in the presence of detergent micelles or phospholipid SUVs. CPZ solutions (3.25 mM) were combined with micelles of 3.1%
Triton X-100 (v/v) (A), SUVs of 22.5 mM DLPC plus 2.5 mM DMPC (B), SUVs of 22.5 mM DLPC plus 2.5 mM DMPS (C), or SUVs of 22.5 mM DLPC
plus 2.5 mM DMPG (D). Samples then were suspended to an initial volume of 5 ml in 150 mM NaCl(aq). Titration was executed as described to generate the
drug titration curve (open circles). Equivalence points were identified at the two peaks of the first derivative plot (filled triangles). The pH at the midpoint
between equivalence points was defined as the pKa of the drug.
Fig. 5. CPZ-induced shape change of various echinocytes in the presence of
vanadate. Cell samples were incubated at 37 jC for up to 31 h with three to
four buffer changes in the absence of sugar supplementation to induce
metabolic depletion (fourth data set), or in the presence of sugar
supplementation to inhibit metabolic depletion. All samples then were
washed and pretreated with 100 AM vanadate. Samples subjected to sugar
supplementation then were treated with lipid SUVs of DLPC (34 AM) or
DLPS (49 or 56 AM) for 40 min at ambient temperature. Samples were
washed and morphological indices were determined (gray bars). All
samples were then treated with 150 AM CPZ at 0 jC for 20 min, and
aliquots were fixed for morphological analysis (filled bars).
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bar C) or DLPC (Fig. 4, bar D), producing echinocytic
morphology, did not affect this ATP increase significantly.
Over the same time period, cells in depletion buffer became
echinocytic without the addition of exogenous lipid, while
ATP levels in such samples dropped by almost 90% over
initial levels (Fig. 4, bar E). Thus, while metabolically
depleted echinocytes do not differ in appearance from
lipid-incorporated echinocytes, their membranes will be
affected by the metabolic depletion process, most notably
in reduction in the levels of polyanionic polyphosphoinosi-
tide lipids in the inner membrane leaflet [14].
3.4. CPZ-induced shape reversal of echinocytes generated
by metabolic depletion or exogenous lipid
The capacity of the stomatogen CPZ to reverse echino-
cytosis was examined. RBC samples incubated for 31 h in
depletion buffer transformed from discocytes (MI = 0.14)
to intermediate-level echinocytes (MI= + 1.94) concurrent
with depletion of polyphosphoinositides in the inner bilayer
leaflet [14]. Comparable echinocytosis was generated in
ATP-replete cells by treatment with exogenous lipid in theFig. 6. CPZ-induced shape change of various echinocytes in the presence of
vanadate—combined results of several experiments. Cell samples were
incubated at 37 jC for up to 33 h with three to five buffer changes in the
presence (open circles,  ’s) or absence (solid circles) of sugar supplements
to induce metabolic depletion. Samples then were washed, pretreated with
100 AM vanadate, and treated with lipid SUVs for 40 min at ambient
temperature: no lipid (solid circles), 0–35 AM DLPC (open circles), 30–90
AM DLPS ( ’s). After washing, samples were treated with 150 AM CPZ at
0 jC for 40–65 min, and aliquots were fixed for morphological analysis. X-
axis, MI before CPZ addition; Y-axis, MI after CPZ treatment minus MI
before CPZ treatment. Positive DMIs indicate echinocytic response to
treatment, while negative DMIs indicate stomatocytic response. Samples
having an initial MI of + 2.5 or greater contained a preponderance of
severely echinocytic cells indicative of membrane shedding, and thus were
excluded from analysis.presence of vanadate, which inhibits transport of PS to the
inner monolayer [15,16]. Control cells were treated with
SUVs (DMPC 34 AM; DLPS 49 or 56 AM), producing MIs
of approximately + 2 (Fig. 5). These echinocytic samples
exhibited different morphological responses to CPZ. The
drug reduced the MI of ATP-depleted echinocytes by 50%,
while the lipid-induced cells reverted at least 66% (Fig. 5).
Shape reversal was blunted slightly in the PS echinocytes
over the PC echinocytes, suggesting a slight charge-induced
accumulation of the cationic drug in PS-enriched outer
leaflets. However, of the samples studied, the least drug-
induced shape reversion was found in the metabolically
depleted echinocytes. This finding was consistent in experi-
ments starting with varying extents of initial echinocytosis
(Fig. 6). Because levels of the phospholipid phosphatidyli-
nositol-4,5-bisphosphate (PIP2) have been shown to dimin-
ish during the course of slow metabolic depletion [14], the
reduced stomatocytic effect of CPZ in metabolically deplet-
ed RBC may be attributed to reduced sequestration of
cationic drug molecules in the membrane inner leaflet.4. Discussion
The work of Sheetz and Singer [11] is among the first to
assert that CPZ induces stomatocytosis in RBCs by inter-
calating preferentially into the membrane inner leaflet.
Demonstration that net negatively charged phospholipids
are localized in the membrane inner leaflet [9,10] provides a
physical rationale for the inner leaflet disposition of cationic
amphipaths like CPZ [11]. Subsequent studies support the
importance of the CPZ charge in membrane binding. Nwa-
for and Coakley [29] assert that the ionic forms of CPZ and
other charged amphipathic drugs participate in Donnan
equilibrium across the RBC membrane. When making the
membrane potential of RBC samples more positive by
reduction of extracellular chloride, they propose that the
concentration of CPZ cation associated with the inner leaflet
decreases to maintain equilibrium, explaining the observed
reduction in stomatocytosis for such samples [29]. Elferink
[21] reports spectrophotometric evidence for charge-induced
sequestration of CPZ in the inner leaflet, demonstrating that
CPZ binds preferentially to the sequestered membrane inner
leaflets of both leaky and resealed ghosts. Additionally,
Elferink provides spectrophotometric evidence that CPZ
binds preferentially to PC liposomes containing (net anion-
ic) PS, compared to PC liposomes, substantiating further the
electrostatic component in the binding of cationic amphi-
paths [21].
However, the above drug binding results are obtained by
spectrophotometric determination of unbound drug concen-
tration in the supernatant following centrifugation in the
ghost study, and following dialysis in the liposome study
[21]. These methods are nonideal in that values must be
corrected for ghost lysate contamination and/or nonspecific
drug binding to the dialysis membrane [21], also in that drug
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unbound drug levels, which often are too low to detect with
consistent accuracy. Recent studies employing NMR, calo-
rimetric, and Langmuir techniques also emphasize the
importance of electrostatic interactions in CPZ membrane
lipid binding, though possible effects of sample pH, phos-
pholipid acyl chain length, and membrane rigidity on their
findings warrant further investigation [30,31].
The present investigation expands upon these previous
studies by providing direct controlled evidence of an elec-
trostatic interaction between CPZ and anionic components
of the membrane inner leaflet. CPZ fluorescence provides
one such direct measurement of drug binding to model
membranes. According to fluorescence theory, increased
CPZ fluorescence indicates an increase in drug binding to
a second component, such as a model membrane system;
this binding should restrict drug vibrational movement,
resulting in greater energy dissipation through increased
fluorescence emission intensity [32]. Moreover, because
CPZ is a highly lipophilic molecule, with a reported
partition coefficient into PC vesicles of about 3500 at 100
AM drug and 1 mg ml 1 lipid [13], the sample fraction of
CPZ bound to model membranes typically is at quantities
large enough to detect accurately and consistently.
The drug fluorescence studies indicate that the hydro-
phobic nature of CPZ drives its general association with
membranes, while the cationic nature of CPZ promotes its
preferential association with the membrane inner leaflet.
Fluorescence of 120 AM CPZ increases when sonicated
zwitterionic lipid (PC) is present, by 320–370% when at
least 0.2 mM in lipid. Drug fluorescence is enhanced further
(up to 92% over PC alone) when the lipid composition is up
to 30 mol% PS. This approximates the percentage of PS
found in the membrane inner leaflet of RBC [14].
The pKa of CPZ also provides a direct measurement of
drug–membrane binding. Insertion into a hydrophobic
environment would be expected to stabilize the deproto-
nated molecule, lowering the observed pKa. Conversely, if
the cationic nature of CPZ contributes significantly to
binding with anionic membrane components, a higher pH
will be required to deprotonate the drug when in an anionic
environment than when in a neutral or zwitterionic envi-
ronment. As a result, the pKa of CPZ should increase as the
anionic nature of the membrane increases.
Results of the drug pKa studies verify the presence of
dominant hydrophobic and significant ancillary electrostatic
interactions in CPZ membrane binding. Hydrophobic inter-
action is evident particularly when assessing the pKa of CPZ
in the presence of Triton X-100, a nonionic polyethylene
glycol ether. In 3.1% (v/v) Triton X-100, a detergent
concentration well above the critical micelle concentration
(reviewed in Ref. [26]), CPZ (3.25 mM) exhibits a pKa of
7.8, significantly lower than the reported pKa values of 8.6–
9.2 for CPZ in free aqueous solution [25,33].
In agreement with the fluorescence studies, results of the
pKa studies indicate an increase in drug–membrane bindingas amphipath negative charge density increases, from non-
ionic (Triton X-100) to zwitterionic (PC) to anionic (PC
with PG). In the presence of PC SUVs (25 mM lipid), pH
titration of CPZ (3.25 mM) discloses a drug pKa value of
8.0, a small but discernible increase from the value observed
with Triton X-100. This pKa value is attributable to the drug,
because the phospholipid functional groups titrate well
away from the observed pKa range [27]. Moreover, this
increase in drug pKa is unaffected when Triton X-100
concentration in the micellar sample is reduced 4-fold to
match the lipid concentration in the membrane outer leaflet
of the PC sample. Thus, while PC is net neutral at physi-
ological pH, the presence of charge on the lipid enhances
drug binding over that observed with nonionic detergent.
Incorporation of net anionic phospholipid into SUVs
should increase the pKa of CPZ even further, indicating
additional enhancement of drug–membrane binding over
that observed with nonionic and zwitterionic amphipathic
phases. Making the lipid 10% in the anionic phospholipid
PS results in a titration curve with no discernible pKa
value (Fig. 3C), due possibly to concurrent titration of
CPZ and the terminal PS amine group [27]. Substitution of
PG for PS produces a drug pKa value of 8.3 (Fig. 3D),
indicating the strongest drug/lipid interaction of any of the
systems studied. These titration studies demonstrate a
preferential interaction between CPZ and anionic mem-
brane lipid components.
Collectively, these fluorescence and pKa studies support
a mechanism by which CPZ accumulates spontaneously in
the cell membrane inner leaflet by a combination of hydro-
phobic and electrostatic interactions. At the outer membrane
surface, composed mainly of zwitterionic lipid, the pKa of
CPZ is around 8.0. At pH 7.4, approximately 25% of the
CPZ population should be electroneutral and capable of
partitioning into the hydrophobic phase [11,21]. As mass
action generates more unprotonated drug, most CPZ at the
outer surface can be incorporated into the bilayer. Once in
the bilayer, the propylamine function eventually encounters
the anionic headgroups of the membrane inner leaflet.
Exposed to the cytoplasmic surface and the cytoplasm at
physiological pH, the terminal amine group reprotonates
and binds with the anionic phospholipids present in the
inner leaflet. In this manner, drug molecules accumulate
preferentially in the membrane inner leaflet, resulting in
stomatogenic inner leaflet expansion.
It has been shown that the MI scale (and the cell shape
progressions represented therein) is continuous, and that
morphologies can be reversed by inducing expansion of the
opposing membrane leaflet [34,35]. Thus, it is possible to
use CPZ to revert echinocytic cells to more discocytic
morphologies (Fig. 5). The present study takes advantage
of this CPZ-induced shape reversion to develop a method-
ology for in situ assessment of drug interactions with
specific anionic lipid components.
To test if CPZ membrane binding is driven by specific
association with membrane PS, CPZ-induced shape reversal
3 Calculated values presented in the Discussion section herein are
based on total inner leaflet localization of native anionic phospholipid in
normal RBC membranes, though reports indicate that 20 mol% of
membrane PA, PI, and PIP2 reside in the outer leaflet [42,43]. The
resulting conclusions are qualitatively unaffected by this difference.
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exogenous PC or PS, in the presence of vanadate. This
treatment inhibits the aminophospholipid translocator, trap-
ping exogenous PS as well as PC in the outer leaflet [15,16].
Should CPZ bind preferentially to PS, then the drug should
partition more evenly between the two membrane leaflets in
PS-induced echinocytes, resulting in less extensive reversal
of echinocytosis compared to PC-treated samples. This
difference is observed, but the extent is minor (Figs. 5 and
6). It is likely that the amount of exogenous PS loaded into
the outer leaflet is small relative to the endogenous PS in the
inner leaflet [14,36], so the effect would be expected to be
subtle.
To assess the importance of phosphatidic acid (PA),
phosphatidylinositol (PI), and the polyphosphoinositides in
CPZ–membrane binding, CPZ-induced shape reversal was
compared for echinocytes produced by slow metabolic
depletion and cells made echinocytic by exogenous PC or
PS. The process of slow metabolic depletion (Fig. 4) results
in net dephosphorylation of PA to diacylglycerol (DAG) and
of PIP2 to PI [14]. Thus, treatment is similar to PS
echinocytosis in reducing the ratio of inner leaflet/outer
leaflet negative charge, while affecting the transbilayer
distribution of PS very little [37].
Echinocytes generated by slow metabolic depletion and
then treated with CPZ exhibit much less shape reversal than
echinocytes generated by exogenous lipid (Figs. 5 and 6).
Because these CPZ incubations were performed at 0 jC, the
observed diminished shape change reversal cannot be attrib-
uted to the drug-induced movement of endogenous PS to the
membrane outer leaflet, which is observed at higher incuba-
tion temperatures [12,38]. The observed reduction in shape
change reversal also does not appear to be due to reduced cell
deformability. Metabolic depletion has been reported to
decrease cell deformability [39], which could explain the
inhibition of drug-induced shape change in such samples. A
more recent report indicates that echinocytes generated by
metabolic depletion exhibit the same decreased deformabil-
ity as replete echinocytes generated by salicylic acid [40].
The shape reversal results implicate PA and PIP2 as
probable binding sites for CPZ. PS is the major negatively
charged lipid in the inner monolayer, making up roughly 30
mol% of inner monolayer phospholipid and 60% of lipid
negative charge [10,14,41–43]. However, PA, PI and the
polyphosphoinositides, while collectively composing only 9
mol% of phospholipid, contribute 40% of the net anionic
charge [10,14,41–43]. Thus, a small change in the molar
levels of these latter lipids can result in significant changes
to inner leaflet anionicity, and possibly to the inner leaflet
propensity of CPZ.
As reported earlier [14], both PA dephosphorylation to
DAG, and PIP2 net dephosphorylation to PI contribute
equally to the combined membrane inner leaflet shrinkage
and outer leaflet expansion leading to echinocytosis in
metabolic depletion. Using values of headgroup surface
areas calculated by J.E. Ferrell (personal communication),dephosphorylation of one PA molecule to DAG results in
membrane inner leaflet shrinkage of 11 A˚2. Assuming that
DAG distributes evenly between inner and outer leaflet [44],
the inner leaflet shrinks by an additional 13 A˚2, while the
outer leaflet expands by the same amount. Thus, the net
relative outward expansion from the dephosphorylation of
one molecule of PA is 37 A˚2. Per molecule of PIP2
dephosphorylated to PI, the inner leaflet surface area con-
tracts by 25 A˚2 [14]. Because similar shrinkage is attribut-
able to the net conversion of PIP2 to PI as with the
conversion from PA to DAG [14], a shrinkage of 37 A˚2
results from roughly 1.5 molecules of PIP2. From these
calculations, degradation of 1 molecule of PA plus 1.5
molecules of PIP2 reduces the number of inner monolayer
negative charges by about 7 [i.e., 1+(1.5 4)], for a net
inner leaflet shrinkage of roughly 74 A˚2. In contrast, a
similar expansion (74 A˚2) in outer leaflet surface area
resulting from intercalation of exogenous PS, resulting from
insertion of 1 to 2 PS molecules, would generate a net
negative charge gain of only 1–2. Thus, for the same level
of echinocytosis, the net shift in negative charge toward the
outer leaflet is about 3.5 to 7 times greater for metabolically
depleted echinocytes than for PS-loaded echinocytes. These
calculations indicate that the amount of exogenous PS
loaded into PS echinocytes is not sufficient to allow direct
comparisons with the metabolically depleted echinocytes.
These findings alone neither confirm nor exclude selective
CPZ binding to PS.3
However, closer analysis of the physical quantities of
lipid and drug in the RBC membrane lends support to the
assertion that CPZ molecules bind to polyphosphoinositide
lipid molecules in preference to PS. The polyphosphoinosi-
tides provide 340 Amol of net monovalent negative charge
per liter of RBC (calculated from values in Ref. [14]).
Assuming total membrane incorporation of CPZ, a sample
of 120 AM CPZ in a 20% HCT suspension of cells yields a
final intramembrane CPZ concentration of 600 Amol/l of
RBC. Thus, the polyphosphoinositides provide enough
monovalent sites for roughly half the drug molecules. The
remaining drug may be retained in the membrane hydrocar-
bon phase as neutral species [22], or bound by other anionic
phospholipids, with PS providing 570 Amol of net negative
charge per liter of cells (calculated from values in Ref. [14]).
Indeed, if CPZ has no preference for a specific anionic
phospholipid headgroup, then the inner leaflet population of
PS alone should provide enough binding sites for most all
the incorporated drug molecules. This situation arises in
metabolic depletion, where polyphosphoinositide levels are
reduced [14] while PS levels in the inner leaflet tend not to
fluctuate greatly [37]. (This analysis excludes the likely
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additional anchorage sites.)
However, CPZ-induced shape reversion is inhibited sig-
nificantly in metabolically depleted cells, indicating that
cationic CPZ molecules do not associate as readily with PS
as with polyphosphoinositide lipid molecules. The higher
negative charge density of the polyphosphoinositides may
offer more stable binding sites for the charged CPZ.
The above data and calculations indicate that polyphos-
phoinositide lipids provide the preponderance of CPZ bind-
ing sites in the membrane inner leaflet, a conclusion
consistent with previous findings. For instance, it is shown
that incubation of RBC with CPZ up to 2 days at 37 jC
results in elevated polyphosphoinositide levels compared to
CPZ-free control samples [45]. Such an effect possibly is
due to physical drug–lipid association, making the lipids
sterically inaccessible to dephosphorylation by phospha-
tases. The connection between CPZ and the polyphosphoi-
nositides also is evident at the neuronal level: CPZ blocks
a1-adrenergic receptors ([1], review), whose activation
ordinarily would result in up-regulation of PIP2 phospho-
diesterases as an intermediary step in neuronal activation
[3]. Thus, the possibility that CPZ could inhibit enzymatic
PIP2 degradation by direct physical interaction with these
lipids in the membrane would provide an alternative path-
way by which neuroleptic effects could be elicited.
Other studies indicate that CPZ also interacts with
protein components in the membrane, [46], such as spectrin
[47,48]. Spectrin has sites of phosphorylation regulated by
calmodulin-dependent spectrin kinases [49], and the possi-
bility of CPZ binding to membrane proteins (perhaps at
phosphorylation sites) is not excluded by the current inves-
tigation. Ongoing studies will ascertain the relative contri-
butions of membrane protein and lipid binding to the
observed CPZ-induced shape effects.Acknowledgements
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